|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
immunomodulatory
|
|
gptkbp:approves
|
gptkb:2013
gptkb:FDA
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
|
|
gptkbp:developed_by
|
gptkb:Celgene_Corporation
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:dosage_form
|
oral capsule
4 mg once daily
|
|
gptkbp:duration
|
until disease progression
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:beer
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pomalidomide
|
|
gptkbp:indication
|
gptkb:healthcare_organization
gptkb:HIV-associated_Kaposi's_sarcoma
|
|
gptkbp:ingredients
|
gptkb:pomalidomide
C13 H11 N3 O4 S
|
|
gptkbp:interacts_with
|
gptkb:warfarin
gptkb:dexamethasone
other immunomodulatory drugs
|
|
gptkbp:is_atype_of
|
L01 X X32
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
approximately 7 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Pomalyst
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitors
|
0 D1 B1 D1 D1 D
|
|
gptkbp:pharmacokinetics
|
modulates immune response
bioavailability 60%
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
diarrhea
constipation
peripheral neuropathy
thrombocytopenia
|
|
gptkbp:target_audience
|
gptkb:relapsed_or_refractory_multiple_myeloma
|
|
gptkbp:type_of
|
191714-01-6
|
|
gptkbp:bfsParent
|
gptkb:Pomalyst
gptkb:Thalomid
|
|
gptkbp:bfsLayer
|
4
|